文献速递前列腺癌

根治性前列腺切除术后生化复发男性的竞争性死亡风险

Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
PubMed 文献 · J Urol · 2020-04-03

该研究基于VA SEARCH数据库1225例根治性前列腺切除术后生化复发男性,采用多变量竞争风险回归分析转移、前列腺癌特异性死亡(PCSM)和其他原因死亡(OCM)的预测因素。中位随访5.6年,20%死于其他原因,6%死于前列腺癌。高龄和合并症与OCM相关,高D'Amico风险及PSA倍增时间<9个月与转移和PCSM相关。

要点

  • 生化复发后10年PCSM为14%(高危肿瘤)和9%(PSA倍增时间<9个月)。
  • 70岁以上且Charlson合并症1-3+者10年OCM为40%-49%,无合并症者为20%。
  • 70多岁伴任何主要合并症者死于其他原因的可能性是死于前列腺癌的2-10倍。

核心结论

  • 根治性前列腺切除术后生化复发男性预后异质性显著,可由现有临床变量解释。
  • 70多岁伴任何主要合并症者死于其他原因的可能性是死于前列腺癌的2至10倍。

研究设计与样本

  • 回顾性分析VA SEARCH数据库中2001至2017年1225例根治性前列腺切除术后生化复发男性。
  • 采用多变量竞争风险回归和递归分割分析。

主要发现

  • 中位随访5.6年(IQR 2.7-9.1),243例(20%)死于其他原因,68例(6%)死于前列腺癌。
  • 高D'Amico肿瘤风险和生化复发时PSA倍增时间小于9个月与转移和PCSM相关(p ≤0.001)。
  • 高龄和更差合并症与OCM相关(p ≤0.001)。
  • 10年PCSM在高危肿瘤者为14%,PSA倍增时间<9个月者为9%。
  • 70岁及以上伴任何Charlson合并症(1-3+)者10年OCM为40%至49%,无合并症者为20%。

关键数值与推荐

  • 高D'Amico肿瘤风险(p ≤0.001)和PSA倍增时间<9个月(p ≤0.001)预测转移和PCSM。
  • 高龄和更差合并症(p ≤0.001)预测OCM。
  • 10年PCSM:高危肿瘤14%,PSA倍增时间<9个月9%。
  • 10年OCM:70岁及以上伴Charlson合并症1-3+者40%-49%,无合并症者20%。
  • 风险亚组10年PCSM范围3%-59%,10年OCM范围17%-50%。

临床怎么用

  • 利用D'Amico风险、PSA倍增时间、年龄和合并症评估生化复发后的竞争性死亡风险。
  • 对70多岁伴合并症者,应权衡其他原因死亡风险高于前列腺癌死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Men with biochemical recurrence after radical prostatectomy need information on competing risks of mortality to inform prognosis and guide treatment. We quantified the risk of prostate cancer metastasis and mortality, and other cause mortality across key clinical predictors. MATERIALS AND METHODS: We analyzed 1,225 men with biochemical recurrence after radical prostatectomy from 2001 to 2017 in the VA SEARCH database. Multivariable competing risks regression was used to identify predictors and quantify cumulative incidence of metastasis, prostate cancer specific mortality and other cause mortality. Recursive partitioning analysis was used to identify optimum variable cut points for prediction of prostate cancer specific mortality and other cause mortality. RESULTS: During a median followup of 5.6 years after biochemical recurrence (IQR 2.7-9.1), 243 (20%) men died of other causes and 68 (6%) died of prostate cancer. Multivariable competing risks regression showed that high D'Amico tumor risk and prostate specific antigen doubling time at biochemical recurrence less than 9 months were associated with metastasis and prostate cancer specific mortality (p ≤0.001). Ten-year prostate cancer specific mortality was 14% and 9% for those with high risk tumors and prostate specific antigen doubling time less than 9 months, respectively. Advanced age and worse comorbidity were associated with other cause mortality (p ≤0.001). Ten-year other cause mortality was higher among men 70 years old or older with any Charlson comorbidity (1-3+) (40% to 49%) compared to those with none (20%). Recursive partitioning analysis identified optimal variable cut points for prediction of prostate cancer specific mortality and other cause mortality, with 10-year prostate cancer specific mortality ranging from 3% to 59% and 10-year other cause mortality ranging from 17% to 50% across risk subgroups. CONCLUSIONS: Among men with biochemical recurrence after radical prostatectomy, there is significant heterogeneity in prognosis that can be explained by available clinical variables. Men in their 70s with any major comorbidity are 2 to 10 times more likely to die of other causes than of prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Daskivich TJ, Howard LE, Amling CL, et al. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. J Urol. 2020. PMID: 32243242. doi:10.1097/JU.0000000000001036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。